LY3471851 for Lupus (ISLAND-SLE Trial)

"In total, this trial is being conducted across 27 different medical centres, including Joint and Muscle Medical Care in Charlotte, North carolina, MetroHealth Medical Center in Cleveland, Ohio, and Inland Rheumatology & Osteoporosis Medical Group in Upland, Connecticut."

"This clinical trial is enrolling 280 patients that have been diagnosed with Libman-Sacks disease. To be eligible, patients must also meet the following criteria: A score of ≥6 on the Total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) during screening, documentation of meeting at least 4 of 11 Revised Criteria for Classification of Systemic Lupus Erythematosus according to the 1997 Update of the 1982 American College of Rheumatology (ACR) criteria for classification of SLE prior to randomization, a clinical diagnosis of SLE at"

"The study in question is no longer active, as the most recent update on clinicaltrials.gov was from 8/9/2022. The trial was first posted on 8/19/2020. Although this research is no longer recruiting, there are presently 124 other trials that are enrolling patients."

"The age limit to participate in this clinical trial is 18-65. If you are not in this age range, there are 17 other trials for people under the age of 18 and 107 for patients over 65."

"LY3471851 is a Phase 2 medication, meaning that while there is some evidence to support its safety, there is none yet to suggest that it is effective. Our team at Power estimates its safety to be a 2."